Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the “Replacement Term Loans”) of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the “Third Amendment Term Loans”) and its outstanding term B loans due 2028 (the “First I.

Business Wire • Dec 12, 2025

BLCO Stock Still 16% Below IPO — Is Silver Point's $38.7 Million Bet a Turning Point?

Connecticut-based Silver Point Capital added nearly 2.6 million BLCO shares in the third quarter, increasing its 13F portfolio by about $38.7 million. The transaction represents 2.8% of reportable U.S. equity assets under management.

The Motley Fool • Dec 3, 2025

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Bausch + Lomb to Participate in Citi Global Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET. A live webcast, as well as a post-event recording, will be available on the I.

Business Wire • Nov 18, 2025

Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation - Analyst/Investor Day Transcript

Bausch + Lomb Corporation ( BLCO ) Bausch + Lomb Corporation - Analyst/Investor Day November 13, 2025 8:30 AM EST Company Participants Brenton Saunders - CEO & Chairman of the Board Osama Eldessouky - Executive VP & CFO Yehia Hashad - Executive VP of Research & Development and Chief Medical officer John Ferris - President of Consumer Mayssa Attar Andrew Stewart - President of Global Pharmaceuticals & International Consumer Yang Yang - President of Vision Care Bryan Reed Luc Bonnefoy - President of Surgical Kelly Swaim Cathleen McCabe Eric Donnenfeld Mark Schaeffer Lejla Vajzovic Conference Call Participants William Trattler Lejla Vajzovic Eric Donnenfeld Mark Schaeffer Patrick Wood - Morgan Stanley, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Kevin Joaquin Joanne Wuensch - Citigroup Inc., Research Division Young Li - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Brenton Saunders CEO & Chairman of the Board So good morning, everyone. Thank you for joining us here.

Seeking Alpha • Nov 18, 2025

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected a total of 691,180 pounds, or 114,037,136 units, of used contact lens, eye care and lens care materials in the United States – the equivalent of more than 2.2 million baseballs.

Business Wire • Nov 10, 2025

Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript

Bausch + Lomb Corporation ( BLCO ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants George Gadkowski Brenton L. Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Yehia Hashad - Executive VP of Research & Development and Chief Medical officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Joanne Wuensch - Citigroup Inc., Research Division Young Li - Jefferies LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Pito Chickering - Deutsche Bank AG, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Douglas Miehm - RBC Capital Markets, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good morning, and welcome to Bausch + Lomb's Third Quarter 2025 Earnings Call.

Seeking Alpha • Oct 29, 2025

Bausch + Lomb Announces Third-Quarter 2025 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. “We're delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our loaded and differentiated pipeline featuri.

Business Wire • Oct 29, 2025

Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Oct 29, 2025

Bausch + Lomb (BLCO) Q3 Earnings Beat Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.17 per share a year ago.

Zacks Investment Research • Oct 29, 2025